grant

Probing Functional States and Inhibition of Flaviviral Proteases Using Nanopore Tweezers

Organization UNIVERSITY OF MASSACHUSETTS AMHERSTLocation HADLEY, UNITED STATESPosted 10 Jun 2021Deadline 31 May 2026
NIHUS FederalResearch GrantFY2025Active SitesAffinityAllosteric SiteAnti-viral AgentsAnti-viral TherapyAssayBindingBioassayBioavailabilityBiochemicalBiological AssayBiological AvailabilityBiophysicsBreakbone Fever VirusCell Communication and SignalingCell SignalingChargeClinicalComplexComputer ModelsComputerized ModelsCryo-electron MicroscopyCryoelectron MicroscopyCytolysinsDENVDENV infectionDataDengueDengue InfectionDengue VirusDengue fever virusDengue virus infectionDengvaxiaDisease OutbreaksDrug InteractionsDrug TargetingDrugsEgypt 101 virusElectron CryomicroscopyEpidemicEquilibriumEsteroproteasesFlavivirusFoundationsGroup B ArbovirusHealthHigh Throughput AssayHumanInfectionIntracellular Communication and SignalingInvestigational DrugsInvestigational New DrugsKineticsLabelLeadLibrariesMeasurementMeasuresMedicationMethodsModern ManMolecularMolecular ConfigurationMolecular ConformationMolecular InteractionMolecular Modeling Nucleic Acid BiochemistryMolecular Modeling Protein/Amino Acid BiochemistryMolecular ModelsMolecular StereochemistryMonitorMotionNatureOrthoflavivirusOutbreaksPb elementPeptidasesPeptide HydrolasesPeptidesPersonsPharmaceutical PreparationsPhysiologic AvailabilityPropertyProtease GeneProteasesProtein DynamicsProtein EngineeringProteinasesProteinsProteolytic EnzymesReactionRecurrenceRecurrentResolutionRoentgen RaysSerine EndopeptidasesSerine ProteaseSerine Protein HydrolasesSerine ProteinasesSerotypingSignal TransductionSignal Transduction SystemsSignalingSubstrate CyclingSubstrate InteractionSystemTechniquesTechnologyTestingThermodynamicThermodynamicsTimeVaccinesViralViral Gene ProductsViral Gene ProteinsViral ProteinsVirus ReplicationWNVWest Nile viral infectionWest Nile virusWest Nile virus infectionWorkX-RadiationX-Ray RadiationX-rayXrayZIKVZIKV infectedZIKV infectionZIKV positiveZika VirusZika virus infectionanomeranti-viral compoundanti-viral drugsanti-viral medicationanti-viral therapeuticanti-viralsbalancebalance functionbiological signal transductionbiophysical foundationbiophysical modelbiophysical principlesbiophysical sciencescomputational modelingcomputational modelscomputer based modelscomputerized modelingconformationconformationalconformational stateconformationallyconformationscontinuous monitoringcryo-EMcryoEMcryogenic electron microscopycryptographydengue viral infectiondesigndesign and constructdesign and constructiondesigningdrug developmentdrug discoverydrug efficacydrug/agentenzyme activityexperienceexperimentexperimental researchexperimental studyexperimentsgenetic protein engineeringguided discoveryguided inquiryheavy metal Pbheavy metal leadhigh throughput screeninghigh-throughput drug screeningimprovedin vivoinfected with West Nile virusinfected with ZIKVinfected with zikainfection with West Nile virusinhibitorinnovateinnovationinnovativeinsightmaltose-binding proteinmolecular modelingmosquito-borne pathogenmosquitoborne pathogennano porenanoporenovelpharmacologicprotein designrational designresidenceresidential buildingresidential siteresolutionsscreeningscreeningssimulationsingle moleculesugartoolviral infectious disease treatmentviral multiplicationviral replicationvirus multiplicationvirus proteinzika infectedzika infectionzika viral infectionzikav
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Project Summary
Flavivirus are major mosquito-borne pathogens infecting millions of people worldwide each year. Currently there

is no antiviral therapy available for treating West Nile, Dengue and Zika viral infections. The first vaccine CYD-

TDV (Dengvaxia) against DENV was approved last year but shows only 56% overall efficacy against the four

dengue serotypes. The flaviviral two-component NS2B/NS3 protease is required for viral replication and thus an

attractive antiviral target. However, extensive screening and rational design efforts have failed to identify any

clinically viable inhibitors at this point. Two key factors have likely contributed to the challenge. First, traditional

screening efforts rely primarily on binding affinity to predict the drug efficacy. Yet, increasing evidence has

emerged to show that the residence time of drug-target interaction is a more reliable predictor of in vivo

pharmacological activity. These kinetic rate parameters are generally not available during early stages of drug

discovery. Second, NS2B/NS3 proteases display complex conformational dynamics during function and

inhibition, which is still poorly understood. This project aims to develop a new label-free single molecular

approach to resolve the conformational states of NS2B/NS3 proteases. Key to the approach is the use of an

innovative nanopore tweezers where the protease is confined with the pore lumen, allowing dynamic structural

changes during substrate or inhibitor binding to be continuously monitored by current fluctuation signals. Analysis

of the current traces will provide a complete profile of binding affinity and kinetic rates as well as the distribution

of conformational states. Specifically, we will first build a nanopore tweezers tool set that is readily tunable for

trapping various flaviviral proteases. Secondly, we will track and analyze the functional states of the NS2B/NS3

protease in the presence of various substrates. Influence of critical residues, substrate, construct design on the

dynamic equilibrium between the “open” and “closed” states will be assessed to provide insight into the

mechanism of protease activity. Finally, the nanopore tweezers will be deployed to determine the structural

dynamics and binding thermodynamics and kinetics profiles of NS2B/NS3 interacting with various inhibitors.

Once the inhibition profiles are established, the nanopore tweezers confined NS2B/NS3 system will be tested

for screening a diverse compound library to identity novel allosteric inhibitors with improved drug-like properties

compared to active-site inhibitors. This work will provide unprecedented kinetic information on the function-

structural dynamics relationship of NS2B/NS3 complex and mechanisms of substrate binding and inhibition, as

well as establish a new paradigm for high-throughput drug screening that is independent of enzymatic activity.

Grant Number: 5R01AI156187-05
NIH Institute/Center: NIH

Principal Investigator: Min Chen

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →